On February 19, 2026, Exicure (XCUR) disclosed one insider trading transaction. Executive Miller Josh sold 8 shares on February 16, 2026.
[Recent Insider Transactions]
Disclosure Date
Position
Name
Transaction Date
Buy/Sell
Quantity
Price per Share/USD
Total Amount/USD
February 19, 2026
Executive
Miller Josh
February 16, 2026
Sell
8
4.08
32.64
January 21, 2026
Shareholder with over 10% ownership
Exicure HiTron Inc.
January 21, 2026
Sell
258,400
4.50
1,162,700
January 20, 2026
Shareholder with over 10% ownership
Exicure HiTron Inc.
January 16, 2026
Sell
734,700
4.50
3,306,400
January 8, 2026
Shareholder with over 10% ownership
Exicure HiTron Inc.
January 7, 2026
Sell
741,300
4.50
3,335,700
December 10, 2025
Shareholder with over 10% ownership
SANGSANGIN INVESTMENT & SECURITIES CO., LTD.
December 8, 2025
Sell
433,300
8.71
3,774,300
November 19, 2025
Executive
Miller Josh
November 16, 2025
Sell
7
3.71
25.97
August 20, 2025
Executive
Miller Josh
August 16, 2025
Sell
9
6.65
59.85
May 23, 2025
Executive
Miller Josh
May 16, 2025
Sell
8
10.06
80.48
March 26, 2025
Shareholder with over 10% ownership
HiTron Systems Inc.
December 26, 2024
Buy
2,900,000
3.00
8,700,000
February 24, 2025
Executive
Miller Josh
February 16, 2025
Sell
9
10.03
90.27
[Company Profile]
Exicure, Inc. was founded on July 9, 2015. The company is a clinical-stage biotechnology firm developing therapeutics based on its proprietary spherical nucleic acid (SNA) technology for immuno-oncology, inflammatory diseases, and genetic disorders.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
US Stock Insider Trading | Exicure disclosed 1 insider transaction on February 19
On February 19, 2026, Exicure (XCUR) disclosed one insider trading transaction. Executive Miller Josh sold 8 shares on February 16, 2026.
[Recent Insider Transactions]
[Company Profile]
Exicure, Inc. was founded on July 9, 2015. The company is a clinical-stage biotechnology firm developing therapeutics based on its proprietary spherical nucleic acid (SNA) technology for immuno-oncology, inflammatory diseases, and genetic disorders.